US FDA recommends steps to improve diversity in clinical trials
FDA issues draft guidance for clinical trial diversity: The FDA is accepting comments on draft guidance suggesting ways that drugmakers and medical device makers can improve diversity in clinical trial participant pools. Goals for a “diversity action plan” should consider the estimated prevalence of the target disease, and the agency will require most makers of new drugs and devices to submit clinical trial diversity plans.